Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radioactive iodine-related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival
    Journal Article

    Boucai, L.; Falcone, J.; Ukena, J.; Coombs, C. C.; Zehir, A.; Ptashkin, R.; Berger, M. F.; Levine, R. L.; Fagin, J. A.
    Journal of Clinical Endocrinology and Metabolism (2018)

    Fulltext@MSK | Save
  • Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era
    Journal Article

    Mato, A.; Jahnke, J.; Li, P.; Mehra, M.; Ladage, V. P.; Mahler, M.; Huntington, S.; Doshi, J. A.
    Haematologica (2018)

    Fulltext@MSK | Save
  • Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
    Journal Article

    Stein, E. M.; Yang, M.; Guerin, A.; Gao, W.; Galebach, P.; Xiang, C. Q.; Bhattacharyya, S.; Bonifacio, G.; Joseph, G. J.
    Health and Quality of Life Outcomes (2018)

    Fulltext@MSK | Save
  • Genomic characterization of spleens in patients with myelofibrosis
    Journal Article

    Zimran, E.; Tripodi, J.; Rampal, R.; Rappoport, F.; Zirkiev, S.; Hoffman, R.; Najfeld, V.
    Haematologica (2018)

    Fulltext@MSK | Save
  • Calculated decisions: MASCC Risk Index for febrile neutropenia
    Journal Article

    Taylor, J.
    Emergency Medicine Practice (2018)

    Fulltext@MSK | Save
  • HOXA9 reprograms the enhancer landscape to promote leukemogenesis
    Journal Article

    Sun, Y.; Zhou, B.; Mao, F.; Xu, J.; Miao, H.; Zou, Z.; Phuc Khoa, L. T.; Jang, Y.; Cai, S.; Witkin, M.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis
    Journal Article

    Pronier, E.; Bowman, R. L.; Ahn, J.; Glass, J.; Kandoth, C.; Merlinsky, T. R.; Whitfield, J. T.; Durham, B. H.; Gruet, A.; Hanasoge Somasundara, A. V.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
    Journal Article

    Mato, A. R.; Roeker, L. E.; Allan, J. N.; Pagel, J. M.; Brander, D. M.; Hill, B. T.; Cheson, B. D.; Furman, R. R.; Lamanna, N.; Tam, C. S.; more...
    American Journal of Hematology (2018)

    Fulltext@MSK | Save
  • Improved sensitivity and specificity for mutated and unmutated class I HLA ligand identifications lead to better immunotherapy target discovery
    Meeting Abstract

    Klatt, M.; Gejman, R.; Mun, S. S.; Dao, T.; Scheinberg, D.
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • Treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DMR) discontinuing dasatinib (DASFREE)
    Meeting Abstract

    Shah, N. P.; Garcia-Gutiérrez, J. V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casares, M. T.; Pane, F.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save